Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liothyronine for HFrEF and Low T3 Syndrome
NCT04112316Phase 2Completed
- Sponsor
- University of Pennsylvania
- Start
- Feb 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liothyronine in heart failure with reduced ejection fraction (HFrEF) and Low T3 syndrome (NTIS), sponsored by University of Pennsylvania. Started Feb 2020; status: completed.
02
Drugs
liothyronine
03
Conditions
heart failure with reduced ejection fraction (HFrEF)Low T3 syndrome (NTIS)
Beyond the preview
Go deeper on NCT04112316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04112316.